Log In Sign up
The largest database of trusted experimental protocols

Msh6 clone bc 44

Manufactured by Biocare Medical
Visit Supplier
Sourced in United States

MSH6 (clone BC/44) is a monoclonal antibody that recognizes the MSH6 protein. MSH6 is a component of the DNA mismatch repair system and plays a role in the recognition of DNA mismatches.

Automatically generated - may contain errors

Lab products found in correlation

Mlh1 clone g168 15, by Biocare Medical (3 mentions) Msh2 clone fe11, by Biocare Medical (2 mentions) Pms2 clone a16 4, by Biocare Medical (2 mentions) Automated staining system, by Agilent Technologies (1 mentions) Polymer detection system, by Agilent Technologies (1 mentions) Hematoxylin, by Agilent Technologies (1 mentions) Pms2 clone mrq 28, by Cell Marque (1 mentions) Msh2 clone g219 1129, by Roche (1 mentions)

Close spelling variants of this product

Anti-human MSH6 (clone BC/44;

3 protocols using msh6 clone bc 44

1

Immunohistochemical Evaluation of MMR Proteins

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Immunohistochemical staining for MMR proteins was performed, using a primary antibody to MLH1 (clone G168–15; Biocare Medical, Concord, CA), MSH2 (clone FE11; Biocare Medical), MSH6 (clone BC/44; Biocare Medical), or PMS2 (clone A16–4; Biocare Medical), and a polymer detection system (Dako, Carpinteria, CA) on an automated staining system (Dako), on the sections (5 μm thick) from the prostate TMA, as described previously.[16 (link)] All stains were quantified independently by 2 pathologists (MS and HM) who were blinded to sample identity. Convincing nuclear staining of each protein in at least 1% of tumor cells was considered to be positive. Cases with discrepancies in the positivity were re-reviewed simultaneously by the 2 pathologists until a consensus was reached.
Sharma M., Yang Z, & Miyamoto H. (2020). Loss of DNA mismatch repair proteins in prostate cancer. Medicine, 99(19), e20124.
+ Open protocol
+ Expand
2

Determining MSI Status in Primary Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
Primary cell lines MSI status was determined using a panel of five markers (BAT25, BAT26, D2S123, D5S346 and BAT40) for Polymerase Chain Reaction (PCR) as well as standard IHC techniques. Briefly, evaluation of MMR protein expression was performed on 5-µm sections of the tissue or cell blocks using antibodies to MLH1 (clone G168-15, 1:75 dilution, Biocare Medical, Concord, CA), PMS2 (clone A16-4, 1:300 dilution, Biocare Medical), MSH6 (clone BC/44, 1:100 dilution, Biocare Medical) and MSH2 (clone FE11, 1:100 dilution, Biocare Medical). Detection was performed using the MACH 3 Mouse HRP-Polymer Detection Kit (Biocare Medical). Chromogenic detection was achieved with diamniobenzidine (Dako) and sections were counterstained with hematoxylin (Dako). Results were evaluated by a board certified gynecologic pathologist experienced in MMR protein immunohistochemical interpretation. Staining of any tumor nuclei was interpreted as positive, with expression by lymphocytes and/or stromal cells considered a positive internal control. Tumors were classified as MSI-low if they had one unstable marker, MSI-high if they had two or more unstable markers and MSI-negative/MSS if all markers were stable by PCR.
Bellone S., Eliana B., Lonardi S., Ferrari F., Centritto F., Masserdotti A., Pettinella F., Black J., Menderes G., Altwerger G., Hui P., Lopez S., de Haydu C., Bonazzoli E., Predolini F., Zammataro L., Cocco E., Ferrari F., Ravaggi A., Romani C., Facchettie F., Sartori E., Odicino F.E., Silasi D.A., Litkouhi B., Ratner E., Azodi M., Schwartz P.E, & Santin A.D. (2016). Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. Gynecologic oncology, 144(1), 146-152.
+ Open protocol
+ Expand
3

Immunohistochemical Profiling of MMR Proteins

Check if the same lab product or an alternative is used in the 5 most similar protocols
Four monoclonal antibodies, which are directed against different mismatch repair (MMR) proteins, were used in the investigation: MLH1 (clone G168-15, 1:50; Biocare, Concorde, CA, USA), MSH2 (clone G219-1129, ready to use; Ventana, Tucson, AZ, USA), MSH6 (clone BC-44; 1:50; Biocare) and PMS2 (clone MRQ-28, 1:50; Cell Marque, Rocklin, CA, USA). For a tumor to be considered MMR-proficient, immunoreactivity for MLH1, MSH2, MSH6, and PMS2 was required, whereas loss of at least one of the four markers characterized MMR-deficient tumors. All MMR-deficient tumors were subsequently tested for microsatellite instability (MSI).
Rössler O., Betge J., Harbaum L., Mrak K., Tschmelitsch J, & Langner C. (2017). Tumor size, tumor location, and antitumor inflammatory response are associated with lymph node size in colorectal cancer patients. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 30(6).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!